Researchers working on an incurable blood cancer can now use a new lab model that could make testing potential new treatments ...

Emiri Nakamura and Professor Koji Eto (Department of Clinical Application) has identified microtubule (MT) destabilization as ...

Each time a cell divides, a small section of each chromosome's protective cap—the telomere—is worn away. Most cells use an ...

These tests are to see whether your CML is responding to treatment. Haematological response Your haematological response is based on whether your blood cells go back to normal levels. You usually have ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers ...

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.

On Monday, Tempus AI Inc. (NASDAQ: TEM) announced the introduction of xM for treatment response monitoring/TRM. This new liquid biopsy assay is designed to detect molecular responses to immune ...

ESH-iCMLf 26th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, Sept 27 – 29, 2024, Prague Scientific Session 1: Top Scoring Abstracts 2024, Friday, September 27 ...

Early molecular responses were achieved in 71.9% of patients, with continuous improvements observed over 24 months. (After a median follow-up of 34 months, 64% of the study population achieved a ...

The trial enrolled 405 patients and evaluated molecular response rates (MRRs). At 48 weeks, 68% of patients taking Scemblix reached MRR, compared to 49% of those on an older TKI.

Early treatment is crucial for reducing mortality and improving outcomes. However, current screening tools for sepsis identification in the prehospital setting are inadequate.

HOUSTON -- An early molecular or cytogenetic response correlated with better long-term survival in heavily pretreated chronic-phase chronic myeloid leukemia (CML) treated with the BCR-ABL ...